The General Hospital Corporation

Theracos, Inc.

Theracos Sub, LLC

Heart Care Partners

Hoechst Aktiengesellschaft

Other

Harvard College

The Brigham and Women's Hospital, Inc.

Massachusetts General Hospital Corporation

Edge Biosystems, Inc.

Sanofi-arentideutschland Gmbh

Advanced Genetic Technologies Corporation

Increvet, Inc.

Brian Seed

Binhua Lv

Jacques Y Roberge

Charles Romeo

Waldemar Kolanus

Yan Feng

Yuanwei Chen

Ge Xu

Baihua Xu

Michael J Hadd

Jiyan Du

Alejandro A Aruffo

Yuelin Wu

John C Seed

Congna Wang

Gerd Walz

Huawei Cheng

Siegfried Stengelin

Qian Liu

Yanli Song

Shengbin Li

Jordan Mechanic

Babak Banapour

Mengzhuang Cai

Lili Zhang

Jia Liu Wolfe

Jiajia Dong

Glen S Cho

David Camerini

Andrew Peterson

Eugen Uhlmann

Min Xu

Paul Habermann

Kun Peng

Leander Lauffer

John L Seed

Alexander Kovtun

David Simmons

Jurgen Haas

Ivan Stamenkovic

Rakesh K Jain

Philip Leder

Michael A Gimbrone, Jr

Edward F Fritsch

Lin Sun

Gerd Zettlmeissl

Elena Getmanova

Wolfgang Ulmer

Yi Yang

Zelin Sheng

Xinzhong Wang

Michael P Bevilacqua

Tae-Ho Lee

Xinxing Tang

Michael Hadd

Patricia Oquendo

Ben Z Stanger

Emily Kim

Janet Allen

Martine Amiot

Chengyu Jiang

Carmen Oquendo

Binhua Xu

Jan Holgersson

Albert Collinson

Chia-Lun Tsai

Vasanthakumar Rajappan

Sengen Sen

Tara Pouyani

Mason Wright Freeman

Masahiro Murakawa

Eun-Chung Park

Chia-Iun Tsai

Chai-Iun Tsai

Provided herein are methods of managing feline diabetes, said methods include administering to a feline in need thereof a total daily dosage of about 5 to 50 mg of Compound 1, having the formula: or a pharmaceutically acceptable form thereof. Also provided herein are methods of managing feline diabetes by administering to a feline in need thereof an effective amount of a SGLT inhibitor, wherein said effective amount is no more than 10 to 30% of the dose required to produce an elevated frequency of diarrhea or loose stool in a healthy feline.

Compound for the management of feline diabetes

Antibody derivatives that have diminished effector function in the initial state owing to the presence of one or more disabling moieties that substantially prevent engagement of the antibody regions responsible for interaction with humoral and cellular immune system effector molecules, and methods of use thereof.

Antibody derivatives with conditionally enabled effector function

Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.

Crystalline form of benzylbenzene SGLT2 inhibitor

Provided are methods of making compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides synthetic intermediates useful for preparing such compounds.

Process for the preparation of benzylbenzene SGLT2 inhibitors

Disclosed herein are methods and compositions related to engineered fragments of the human transglutaminase-related protein family, described herein as engineered transglutaminase barrel proteins (ETBPs), that have utility as high affinity, high selectivity target-binding proteins offering advantages as antibody equivalents for therapeutic, analytical, manufacturing and research purposes. ETBPs differ from naturally occurring human transglutaminase fragments by the addition, deletion, replacement and/or substitution of the naturally occurring amino acid sequence. ETBPs can be easily expressed in prokaryotic cells and in many cases can be purified by a simple solubilization and precipitation method.

Engineered transglutaminase barrel proteins

The invention features compositions based on thioredoxin-like fold protein domains described as engineered thioredoxin-like fold proteins (ETRXs). These proteins include one or more artificially diversified thioredoxin-like fold protein domains; each domain may be originated from the same or different thioredoxin-like fold protein domains. Features of the invention also include methods for identifying and preparing an enriched composition of target binding, loop-diversified ETRXs with additional sequence variations to improve affinity, stability, selectivity, or solubility. The invention also features compositions of ETRXs substituted with prosthetic groups, polymers, proteins, nucleic acids, carbohydrates, metals, natural or synthetic small molecules and toxins.

Engineered thioredoxin-like fold proteins

Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions that are affected by SGLT inhibition.

Deuterated benzylbenzene derivatives and methods of use

The present invention provides methods and compositions for treating various diseases through selective killing of targeted cells using a combinatorial targeting approach. The invention features protoxin fusion proteins containing a cell targeting moiety and, a modifiable activation moiety which is activated by an activation moiety not naturally operably found in, on, or in the vicinity of a target cell. These methods also include the combinatorial use of two or more therapeutic agents, at minimum comprising a protoxin and a protoxin activator, to target and destroy a specific cell population.

Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting

Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.

Benzylbenzene derivatives and methods of use

Provided are methods of treating obesity and effecting desired weight loss or preventing undesired weight gain by administration of a preferential muscarinic acetylcholine receptor Mantagonist, optionally with at least one antidepressant other than a selective muscarinic acetylcholine receptor Mantagonist. The preferential muscarinic acetylcholine receptor Mantagonist, optionally can be administered with an anti-obesity agent, for example, an anorexiant. The invention also provides for pharmaceutical compositions and kits for administration of at least one selective muscarinic acetylcholine receptor Mantagonist in combination with at least one antidepressant other than a selective muscarinic acetylcholine receptor Mantagonist.

[object Object]

Provided are methods of treating psychological diseases and conditions by administration of a preferential muscarinic acetylcholine receptor Mantagonist, optionally with at least one antidepressant other than a selective muscarinic acetylcholine receptor Mantagonist. The invention also provides for pharmaceutical compositions and kits for administration of at least one selective muscarinic acetylcholine receptor Mantagonist in combination with at least one antidepressant other than a selective muscarinic acetylcholine receptor Mantagonist.

Growing community of inventors

Boston, MA, United States of America

Brian Seed